In a reversal, Gilead has submitted a request to the US FDA to rescind the orphan drug designation it was granted for the investigational antiviral remdesivir for the treatment of COVID-19. Earlier this month, Gilead was granted the designation because the potential antiviral would help to treat COVID-19, which currently affects fewer than 200,000 patients in the US. If the company had kept the designation and remdesivir won approval, the treatment would have received seven years of orphan drug and tax credits for some of the research done on remdesivir. Learn More